Department of Immunology, Laboratory Medical Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
Methods Mol Biol. 2022;2453:61-77. doi: 10.1007/978-1-0716-2115-8_4.
Identification of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements in acute lymphoblastic leukemia (ALL) patients at initial presentation are crucial for monitoring of minimal residual disease (MRD) during subsequent follow-up and thereby for appropriate risk-group stratification. Here we describe how RNA-Seq data can be generated and subsequently analyzed with ARResT/Interrogate to identify possible MRD markers. In addition to the procedures, possible pitfalls will be discussed. Similar strategies can be employed for other lymphoid malignancies, such as lymphoma and myeloma.
在初始表现时鉴定急性淋巴细胞白血病（ALL）患者的免疫球蛋白（IG）和 T 细胞受体（TR）基因重排对于随后的随访期间监测微小残留病（MRD）以及进行适当的危险分层至关重要。在这里，我们描述了如何生成 RNA-Seq 数据，然后使用 ARResT/Interrogate 进行分析以识别可能的 MRD 标志物。除了程序外，还将讨论可能出现的问题。类似的策略可用于其他淋巴样恶性肿瘤，如淋巴瘤和骨髓瘤。
